サンプル依頼リスト カート
  • English
  • Korean
表紙：遺伝子発現解析の世界市場-2023年～2030年
市場調査レポート
商品コード
1345424

遺伝子発現解析の世界市場-2023年～2030年

Global Gene Expression Analysis Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
遺伝子発現解析の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の遺伝子発現解析市場は、2022年に45億米ドルに達し、2023-2030年の予測期間中にCAGR 8.7％で成長し、2030年には86億米ドルに達すると予測されています。

遺伝子発現解析は、機能的遺伝子産物、機能的RNA種、タンパク質産物を合成するために遺伝子がどのように転写されるかを研究するものです。遺伝子制御の研究は、分化などの正常な細胞プロセスや異常または病理学的プロセスに関する洞察を提供します。遺伝子発現解析は、正常な生物学的および疾患プロセスにおける遺伝子発現の差の役割や、バイオマーカーシグネチャーの同定および検証において貴重な洞察を提供します。

リアルタイムPCRは、遺伝子発現プロファイルの差異を検証するための標準的な手法です。次世代シークエンシングによるトランスクリプトームシークエンシングは、仮説中立的なアプローチを用いて差次的発現遺伝子の発見を可能にします。遺伝子発現プロファイリングの進歩は、より良い結果をもたらします。

さらに、レーザーキャプチャーマイクロダイセクション（LCM）とマイクロアレイ技術は、遺伝子発現の研究に次の革命をもたらしています。人工知能と機械学習の統合は、対数が手順全体にわたって正確なデータを提供するように訓練されるため、より良い結果をもたらします。これらは、今後一定期間において市場を牽引すると予想される要因です。

ダイナミクス

技術進歩の拡大

NGSや分子サービスなどの技術進歩の高まりが、遺伝子発現サービスの需要を押し上げています。さらに、ゲノムデータベースの開発、ゲノミクスに対する政府資金の増加、個別化医療の成長が市場を牽引する可能性が高いです。ゲノミクスに対する政府資金の増加は、遺伝子発現解析市場の発展につながる主な要因の1つです。

2023年3月、イルミナは臨床次世代シーケンサー（NGS）データの三次解析を提供するクラウドベースのソフトウェア、Connected Insightsを新たにリリースしました。Connected Insightsは、NGSアプリケーション全体のディスカバリーのペースに合わせて拡張する、完全に統合されたソフトウェアエコシステムを構築するための次のステップです。

人工知能（AI）の統合

遺伝子変異については全ゲノムシーケンス、遺伝子発現についてはRNA-seqやマイクロアレイを用いた統計解析や予測解析にAI/MLアルゴリズムを適用することで、正確でより信頼性の高いプロファイリングが可能になるため、最近よく見られるようになっています。遺伝子発現マイクロアレイデータでは、遺伝子選択アプローチのような機械学習ベースの特徴選択アプローチが、プールから必要な遺伝子を選択するのに役立ちます。

2023年6月1日、DNAシーケンシングとアレイベース技術の世界的リーダーであるイルミナ社は、患者の病気を引き起こす遺伝子変異をかつてない精度で予測する人工知能（AI）アルゴリズムである新しいPrimateAI-3Dを発表しました。PrimateAI-3Dは、個別化ゲノム医療の成功に直面する重大な課題に対処します。また、遺伝子リスク予測の精度を大幅に向上させました。

遺伝子発現プロファイリングの多額の費用

シーケンシングに伴う多額の費用が、過去10年間の市場成長にとって大きな課題となっています。2003年、ヒトゲノム計画によって解読された最初のヒトゲノムは、27億米ドルの資金を必要としました。しかし、ゲノミクスの分野では、シーケンスの高速化と費用の削減を目指した技術開発がいくつか行われてきました。

NHGRI（National Human Genome Research Institute、米国）は、資金提供を受けているさまざまなゲノム配列決定センターにおける配列決定コストを長年にわたって追跡し、ヒトゲノム計画後の数年間のゲノム配列決定コストを推定してきました。このデータに基づき、NHGRIは、2006年には完成したヒトゲノムシーケンスを作成するのに2,000万～2,500万米ドル以上かかったのが、2015年後半には、高品質のヒト全ゲノムシーケンスドラフトを開発する価格は1,500米ドルを下回ったと推定しています。全ゲノム配列の作成コストは、一般的に1,000米ドルを下回っています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 技術進歩の拡大
      • 人工知能（AI）の統合
    • 抑制要因
      • 遺伝子発現プロファイリングの多額の費用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 製品タイプ別

  • 機器
    • PCR（ポリメラーゼ連鎖反応）
    • NGS（次世代シーケンサー）
    • マイクロアレイ
    • その他
  • サービス
  • その他

第8章 技術別

  • RNA発現
    • RNAシーケンス
    • ノーザンブロッティング
    • DNAマイクロアレイ
    • その他
  • プロモーター解析
    • ゲルシフトアッセイ
    • クロマチン免疫沈降
    • In Vitro転写ランオンアッセイ
  • タンパク質発現および翻訳後修飾発現
    • 免疫アッセイ
    • 質量分析
    • ウェスタンブロッティング
    • 2Dゲル電気泳動
    • その他
  • その他

第9章 用途別

  • 創薬・医薬品開発
  • 臨床診断
  • バイオテクノロジー・微生物学
  • その他

第10章 エンドユーザー別

  • バイオテクノロジー・製薬企業
  • 診断検査室
  • 学術研究センター
  • CRO（医薬品開発業務受託機関）
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • QIAGEN
    • 企業概要
    • 製品タイプ別のポートフォリオと説明
    • 財務概要
    • 主な動向
  • Merck KGaA
  • Genscript Biotech Corporation
  • Bio-Rad Laboratories
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • Promega Corporation
  • Agilent Technologies
  • Lonza Group Ltd.
  • New England Biolabs Inc.

第14章 付録

目次
Product Code: BT2291

Overview

Global Gene Expression Analysis Market reached US$ 4.5 billion in 2022 and is expected to reach US$ 8.6 billion by 2030 growing with a CAGR of 8.7% during the forecast period 2023-2030.

Gene expression analysis is the study of how genes are transcribed to synthesize functional gene products, functional RNA species, or protein products. The study of gene regulation provides insights into normal cellular processes, such as differentiation and abnormal or pathological processes. Gene expression analysis provides valuable insight into the role of differential gene expression in normal biological and disease processes and in the identification and verification of biomarker signatures.

Real-time PCR is the gold-standard technique for the verification of differential gene expression profiles. Transcriptome sequencing by next-generation sequencing enables the discovery of differentially expressed genes using a hypothesis-neutral approach. The advancements in gene expression profiling lead to better outcomes.

Furthermore, the Laser capture microdissection (LCM) and microarray technology are providing the next revolution in the study of gene expression. Integration of artificial intelligence and machine learning give better outcomes as the logarithms are trained to provide accurate data during the entire procedure. These are the factors which are expected to drive the market in the forthcoming period.

Dynamics

Rising Technological Advancements

The growing technological advancements such as NGS and molecular services are boosting the demand for gene expression services. Additionally, the development of genomic databases, increased government funding for genomics, and personalized medicine growth will likely drive the market. Increasing government funding for genomics is one of the major factors leading to the development of the gene expression analysis market.

In March 2023, Illumina released its new Connected Insights, cloud-based software that provides tertiary analysis for clinical next-generation sequencing (NGS) data. Connected Insights is the next step in creating a fully integrated software ecosystem that scales with the pace of discovery across NGS applications.

Integration of artificial intelligence (AI)

Application of AI/ML algorithms for statistical and predictive analyses using whole genome sequencing for gene variants, and RNA-seq and microarrays for gene expression is observed these days as the outcome is accurate and more reliable for profiling. In gene expression microarray data, machine learning-based feature selection approaches like gene selection approaches will help to select the required genes from the pool.

On June 1, 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, launched the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. PrimateAI-3D addresses a critical challenge facing the successful implementation of personalized genomic medicine. It also greatly improved the accuracy of genetic risk prediction.

High Costs of Gene Expression Profiling

The high cost associated with sequencing posed a significant challenge to market growth in the last decade. In 2003, the first human genome sequenced by the Human Genome Project required ~USD 2.7 billion in funding. However, several technological developments have taken place in the field of genomics, which were aimed at increasing the speed and reducing the expenses associated with sequencing.

The NHGRI (National Human Genome Research Institute, US) has tracked the sequencing costs at its various funded genome sequencing centers for many years and estimated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, it would have likely cost over USD 20-25 million to generate a finished human genome sequence, while by late 2015, the price to develop a high-quality whole human genome sequence draft had fallen below USD 1,500. The cost to generate a whole-exome sequence was generally below USD 1,000.

For more details on this report - Request for Sample

Segment Analysis

The global gene expression analysis market is segmented based on product type, technique, application, end-user and region.

The RNA Sequencing Segment Accounted for Approximately 42.9% of the Market Share

RNA Sequencing is expected to hold the largest market share as the technique uses next-generation sequencing (NGS), AI to reveal the presence and quantity of RNA in a biological sample. With the advent of machine learning and other technological advancements, gene expression analysis accuracy has increased.

In March 2023, Alithea Genomics, a Lausanne-based start-up that specializes in high-throughput RNA sequencing, secured a CHF 500,000 Tech Growth loan from the Foundation for Technological Innovation (FIT). RNA sequencing is a valuable tool in biomedical research, allowing scientists to examine gene expression, discover new biomarkers, and develop new drugs. Alithea Genomics aims to address this challenge with its proprietary technology, Bulk RNA Barcoding followed by sequencing (BRB-seq), which can prepare thousands of RNA samples for sequencing in a single tube, unlike standard RNA-seq sample preparation

Geographical Analysis

North America accounted for Approximately 39.2% of the Market Share in 2022

North America is dominating the global gene expression analysis market, with the United States accounting as the major contributor to the market. The United States spends the most compared to other countries on genomics research, corresponding to 40% of worldwide public funding.

Citizens and taxpayers of several countries have funded much of the research and have expectations about access to the resulting information and knowledge. While access to knowledge gained from all publicly funded research is desired, access is essential for fields that have a broad social impact and stimulate public dialogue. Innovate UK has up to £5 million to support capital investment in equipment that increases the UK's capacity to produce and commercialize genomic analysis technologies.

Most of the major key players are based in North America such as Illumina, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Luminex Corporation, etc. are contributing to making this region the largest shareholder in gene expression analysis market. For instance, in Jan 2022, Illumina Inc. announced a multi-year agreement with Nashville Biosciences LLC to increase medicines development via large-scale genomics and also the formation of clinical-genomic resource that is pre-eminent with the help of Illumina's next-generation sequencing (NGS)

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gene expression analysis market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting healthcare innovations worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to industries.

The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of genetic research and development activities. This has led to delays in the completion of trials and the availability of new diagnostic procedures and therapies, which has affected the market.

By Product Type

  • Instruments
    • PCR (Polymerase Chain Reaction)
    • NGS (Next Gen Sequencing)
    • Microarray
    • Others
  • Services
  • Others

By Technique

  • RNA Expression
    • PCR
    • RNA Sequencing
    • Northern Blotting
    • DNA Microarrays
    • Others
  • Promotor Analysis
    • Gel Shift Assays
    • Chromatin Immunoprecipitation
    • In Vitro transcription Run on Assays
    • Others
  • Protein Expression & Post Translational Modification Expression
    • Immunoassays
    • mass spectrometry
    • Western Blotting
    • 2D gel Electrophoresis
    • Others
  • Others

By Application

  • Drug Discovery and Development
  • Clinical Diagnostics
  • Biotechnology and Microbiology
  • Others

By End User

  • Biotechnology & Pharmaceutical Companies
  • Diagnostic Laboratories
  • Academic Research Centers
  • Contract Research Organisation
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In May 2023, 10x Genomics, Inc., a leader in single cell and spatial biology, announced today the commercial availability of a new Visium CytAssist Gene and Protein Expression product to expand the breadth of the Visium CytAssist spatial analysis capabilities. It enables researchers to simultaneously produce highly multiplexed protein and whole transcriptome RNA data mapped together from the same formalin-fixed, paraffin-embedded (FFPE) tissue section at high spatial resolution.
  • On June 1, 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, launched the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. PrimateAI-3D addresses a critical challenge facing the successful implementation of personalized genomic medicine. It also greatly improved the accuracy of genetic risk prediction.

Competitive Landscape

The major global players in the gene expression analysis market include: QIAGEN, Merck KGaA, Genscript Biotech Corporation, Bio-Rad Laboratories, Takara Bio Inc., Thermo Fisher Scientific, Inc., Promega Corporation, Agilent Technologies, Lonza Group Ltd., New England Biolabs Inc. among others.

Why Purchase the Report?

  • To visualize the global gene expression analysis segmentation based on product type, technique, application, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of gene expression analysis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global gene expression analysis market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technique
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Technological Advancements
      • 4.1.1.2. Integration of artificial intelligence (AI)
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Gene Expression Profiling
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments
    • 7.2.1. PCR (Polymerase Chain Reaction)
    • 7.2.2. NGS (Next Gen Sequencing)
    • 7.2.3. Microarray
    • 7.2.4. Others
  • 7.3. Services
  • 7.4. Others

8. By Technique

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 8.1.2. Market Attractiveness Index, By Technique
  • 8.2. RNA Expression
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. RNA Sequencing
    • 8.2.4. Northern Blotting
    • 8.2.5. DNA Microarrays
    • 8.2.6. Others
  • 8.3. Promotor Analysis
    • 8.3.1. Gel Shift Assays
    • 8.3.2. Chromatin Immunoprecipitation
    • 8.3.3. In Vitro transcription Run on Assays
  • 8.4. Protein Expression & Post Translational Modification Expression
    • 8.4.1. Immunoassays
    • 8.4.2. mass spectrometry
    • 8.4.3. Western Blotting
    • 8.4.4. 2D gel Electrophoresis
    • 8.4.5. Others
  • 8.5. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Drug Discovery and Development
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Clinical Diagnostics
  • 9.4. Biotechnology and Microbiology
  • 9.5. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Biotechnology & Pharmaceutical Companies
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diagnostic Laboratories
  • 10.4. Academic Research Centers
  • 10.5. Contract Research Organisation
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. UK
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. QIAGEN
    • 13.1.1. Company Overview
    • 13.1.2. Product Type Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Merck KGaA
  • 13.3. Genscript Biotech Corporation
  • 13.4. Bio-Rad Laboratories
  • 13.5. Takara Bio Inc.
  • 13.6. Thermo Fisher Scientific, Inc.
  • 13.7. Promega Corporation
  • 13.8. Agilent Technologies
  • 13.9. Lonza Group Ltd.
  • 13.10. New England Biolabs Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us